Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EBT (2016 - 2025)

Marimed (MRMD) has disclosed EBT for 15 consecutive years, with -$182000.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 45.67% to -$182000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.6 million, a 36.14% increase, with the full-year FY2024 number at -$4.0 million, up 39.84% from a year prior.
  • EBT was -$182000.0 for Q3 2025 at Marimed, up from -$579000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $11.4 million in Q2 2021 to a low of -$9.6 million in Q4 2023.
  • A 5-year average of $1.5 million and a median of $768000.0 in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 1099.1% in 2021, then crashed 750.5% in 2025.
  • Marimed's EBT stood at $768000.0 in 2021, then surged by 258.72% to $2.8 million in 2022, then crashed by 449.55% to -$9.6 million in 2023, then surged by 66.22% to -$3.3 million in 2024, then soared by 94.41% to -$182000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBT are -$182000.0 (Q3 2025), -$579000.0 (Q2 2025), and -$2.6 million (Q1 2025).